Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-7bb8b95d7b-s9k8s Total loading time: 0 Render date: 2024-09-18T23:57:08.591Z Has data issue: false hasContentIssue false

Chapter 38 - Hematopoietic Cell Transplants for Hodgkin Lymphoma

from Section 12 - Hematopoietic Cell Transplants for Lymphomas: Changing Indications

Published online by Cambridge University Press:  24 May 2017

By
Paolo F. Caimi
Edited by
Hillard M. Lazarus ,
Robert Peter Gale ,
Armand Keating ,
Andrea Bacigalupo ,
Reinhold Munker  and
Kerry Atkinson
Edited in association with
Syed Ali Abutalib
Hillard M. Lazarus
Affiliation:
Case Western Reserve University, Ohio
Robert Peter Gale
Affiliation:
Imperial College London
Armand Keating
Affiliation:
University of Toronto
Andrea Bacigalupo
Affiliation:
Ospedale San Martino, Genoa
Reinhold Munker
Affiliation:
Louisiana State University, Shreveport
Kerry Atkinson
Affiliation:
University of Queensland
Syed Ali Abutalib
Affiliation:
Midwestern Regional Medical Center, Cancer Treatment Centers of America, Chicago
Get access
Type
Chapter
Information
Hematopoietic Cell Transplants
Concepts, Controversies and Future Directions
 , pp. 361 - 371
Publisher: Cambridge University Press
Print publication year: 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Townsend, W, Linch, D. Hodgkin’s lymphoma in adults. Lancet 2012;380(9844):836–847.CrossRefGoogle ScholarPubMed
Kuruvilla, J, Keating, A, Crump, M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011;117(16):4208–4217.CrossRefGoogle Scholar
Carella, AM, Congiu, AM, Gaozza, E, Mazza, P, Ricci, P, Visani, G, et al. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin’s disease patients: an Italian study group report. J Clin Oncol 1988;6(9):1411–1416.CrossRefGoogle ScholarPubMed
Linch, DC, Winfield, D, Goldstone, AH, Moir, D, Hancock, B, McMillan, A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 1993;341(8852):1051–1054.CrossRefGoogle ScholarPubMed
Carella, AM. Role of hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma. Mediterr J Hematol Infect Dis 2012;4(1):e2012059.CrossRefGoogle ScholarPubMed
Schmitz, N, Pfistner, B, Sextro, M, Sieber, M, Carella, AM, Haenel, M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002;359(9323):2065–2071.CrossRefGoogle ScholarPubMed
Bierman, PJ, Bagin, RG, Jagannath, S, Vose, JM, Spitzer, G, Kessinger, A, et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin’s disease: long-term follow-up in 128 patients. Ann Oncol 1993;4(9):767–773.CrossRefGoogle ScholarPubMed
Crump, M, Smith, AM, Brandwein, J, Couture, F, Sherret, H, Sutton, DM, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin’s disease: importance of disease status at transplant. J Clin Oncol 1993;11(4):704–711.CrossRefGoogle ScholarPubMed
Reece, DE, Nevill, TJ, Sayegh, A, Spinelli, JJ, Brockington, DA, Barnett, MJ, et al. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin’s disease. Bone Marrow Transplant 1999;23(11):1131–1138.CrossRefGoogle ScholarPubMed
Stuart, MJ, Chao, NS, Horning, SJ, Wong, RM, Negrin, RS, Johnston, LJ, et al. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin’s disease. Biol Blood Marrow Transplant 2001;7(10):552–560.CrossRefGoogle ScholarPubMed
Stewart, DA, Guo, D, Gluck, S, Morris, D, Chaudhry, A, deMetz, C, et al. Double high-dose therapy for Hodgkin’s disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 2000;26(4):383–388.CrossRefGoogle ScholarPubMed
Moskowitz, CH, Nimer, SD, Zelenetz, AD, Trippett, T, Hedrick, EE, Filippa, DA, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97(3):616–623.CrossRefGoogle ScholarPubMed
Visani, G, Stefani, PM, Capria, S, Malerba, L, Galieni, P, Gaudio, F, Specchia, G, et al. Bendamustine, etoposide, cytarabine and melphalan (BEEAM) followed by autologous stem cell transplantation produce a 3-year progression-free survival of 75% in heavily pre-treated Hodgkin and non-Hodgkin lymphoma. Blood 2013;122(21):2134.CrossRefGoogle Scholar
Andre, M, Henry-Amar, M, Pico, JL, Brice, P, Blaise, D, Kuentz, M, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin’s disease induction failure: a case-control study. Societe Francaise de Greffe de Moelle. J Clin Oncol 1999;17(1):222–229.CrossRefGoogle ScholarPubMed
Lazarus, HM, Rowlings, PA, Zhang, MJ, Vose, JM, Armitage, JO, Bierman, PJ, et al. Autotransplants for Hodgkin’s disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999;17(2):534–545.CrossRefGoogle ScholarPubMed
Hertzberg, M. Relapsed/refractory Hodgkin lymphoma: what is the best salvage therapy and do we need RIC-alloSCT? Hematol Oncol Clin North Am 2014;28(1):123–147.CrossRefGoogle ScholarPubMed
Bains, T, Chen, AI, Lemieux, A, Hayes-Lattin, BM, Leis, JF, Dibb, W, et al. Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma 2014;55(3):583–587.CrossRefGoogle ScholarPubMed
Nieto, Y, Popat, U, Anderlini, P, Valdez, B, Andersson, B, Liu, P, et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin’s lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant 2013;19(3):410–417.CrossRefGoogle ScholarPubMed
Shafey, M, Duan, Q, Russell, J, Duggan, P, Balogh, A, Stewart, DA. Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma 2012;53(4):596–602.CrossRefGoogle ScholarPubMed
Josting, A, Sieniawski, M, Glossmann, JP, Staak, O, Nogova, L, Peters, N, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin’s lymphoma: results of a multicenter phase II study. Ann Oncol 2005;16(8):1359–1365.CrossRefGoogle ScholarPubMed
Josting, A, Muller, H, Borchmann, P, Baars, JW, Metzner, B, Dohner, H, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin’s lymphoma. J Clin Oncol 2010;28(34):5074–5080.CrossRefGoogle ScholarPubMed
Fung, HC, Stiff, P, Schriber, J, Toor, A, Smith, E, Rodriguez, T, et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood Marrow Transplant 2007;13(5):594–600.CrossRefGoogle ScholarPubMed
Morschhauser, F, Brice, P, Ferme, C, Divine, M, Salles, G, Bouabdallah, R, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin’s lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 2008;26(36):5980–5987.CrossRefGoogle ScholarPubMed
Biswas, T, Culakova, E, Friedberg, JW, Kelly, JL, Dhakal, S, Liesveld, J, et al. Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma. Radiother Oncol 2012;103(3):367–372.CrossRefGoogle ScholarPubMed
Kahn, S, Flowers, C, Xu, Z, Esiashvili, N. Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma? Int J Radiat Oncol Biol Phys 2011;81(1):175–180.CrossRefGoogle ScholarPubMed
Poen, JC, Hoppe, RT, Horning, SJ. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin’s disease: the impact of involved field radiotherapy on patterns of failure and survival. Int J Radiat Oncol Biol Phys 1996;36(1):3–12.CrossRefGoogle ScholarPubMed
von Tresckow, B, Muller, H, Eichenauer, DA, Glossmann, JP, Josting, A, Boll, B, et al. Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant. Leuk Lymphoma 2014;55(8):1922–1924.CrossRefGoogle ScholarPubMed
Martinez, C, Canals, C, Sarina, B, Alessandrino, EP, Karakasis, D, Pulsoni, A, et al. Identification of prognostic factors predicting outcome in Hodgkin’s lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol 2013;24(9):2430–2434.CrossRefGoogle ScholarPubMed
Gajewski, JL, Phillips, GL, Sobocinski, KA, Armitage, JO, Gale, RP, Champlin, RE, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J Clin Oncol 1996;14(2):572–578.CrossRefGoogle ScholarPubMed
Milpied, N, Fielding, AK, Pearce, RM, Ernst, P, Goldstone, AH. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’s disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996;14(4):1291–1296.CrossRefGoogle ScholarPubMed
Peniket, AJ, Ruiz de Elvira, MC, Taghipour, G, Cordonnier, C, Gluckman, E, de Witte, T, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003;31(8):667–678.CrossRefGoogle ScholarPubMed
Kharfan-Dabaja, MA, Hamadani, M, Sibai, H, Savani, BN. Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all! Bone Marrow Transplant 2014;49(5):599–606.CrossRefGoogle Scholar
Sarina, B, Castagna, L, Farina, L, Patriarca, F, Benedetti, F, Carella, AM, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010;115(18):3671–3677.CrossRefGoogle ScholarPubMed
Sureda, A, Robinson, S, Canals, C, Carella, AM, Boogaerts, MA, Caballero, D, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26(3):455–462.CrossRefGoogle ScholarPubMed
Peggs, KS, Hunter, A, Chopra, R, Parker, A, Mahendra, P, Milligan, D, et al. Clinical evidence of a graft-versus-Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005;365(9475):1934–1941.CrossRefGoogle ScholarPubMed
Anderlini, P, Saliba, R, Acholonu, S, Okoroji, GJ, Donato, M, Giralt, S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2005;35(10):943–951.CrossRefGoogle ScholarPubMed
Sureda, A, Canals, C, Arranz, R, Caballero, D, Ribera, JM, Brune, M, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study − a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012;97(2):310–317.CrossRefGoogle ScholarPubMed
Anderlini, P, Saliba, RM, Ledesma, C, Chancoco, CM, Alexander, T, Alousi, A, Hosing, CM, et al. Reduced-intensity conditioning (RIC) and allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory Hodgkin lymphoma (HL) in the brentuximab vedotin era: Favorable overall and progression-free survival (OS/PFS) with low transplant-related mortality (TRM). Blood 2013;122(21):410.CrossRefGoogle Scholar
Devetten, MP, Hari, PN, Carreras, J, Logan, BR, van Besien, K, Bredeson, CN, et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2009;15(1):109–117.CrossRefGoogle ScholarPubMed
Burroughs, LM, O’Donnell, PV, Sandmaier, BM, Storer, BE, Luznik, L, Symons, HJ, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14(11):1279–1287.CrossRefGoogle ScholarPubMed
Castagna, L, Bramanti, S, Furst, S, Sarina, B, El-Cheikh, J, Granata, A, et al. Lower relapse and better PFS among chemosensitive patients undergoing allogeneic transplantation by haploidentical compared with HLA-identical donor: results on a cohort of 94 patients with Hodgkin’s lymphoma. Blood 2013;122(21):2144.CrossRefGoogle Scholar
Majhail, NS, Weisdorf, DJ, Wagner, JE, Defor, TE, Brunstein, CG, Burns, LJ. Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood 2006;107(9):3804–3807.CrossRefGoogle ScholarPubMed
Marcais, A, Porcher, R, Robin, M, Mohty, M, Michalet, M, Blaise, D, et al. Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin’s lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2013;98(9):1467–1475.CrossRefGoogle ScholarPubMed
Peggs, KS, Kayani, I, Edwards, N, Kottaridis, P, Goldstone, AH, Linch, DC, et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin’s lymphoma. J Clin Oncol 2011;29(8):971–978.CrossRefGoogle ScholarPubMed
Anderlini, P, Saliba, R, Acholonu, S, Okoroji, GJ, Ledesma, C, Andersson, BS, et al. Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. Leuk Lymphoma 2012;53(6):1239–1241.CrossRefGoogle ScholarPubMed
Younes, A, Gopal, AK, Smith, SE, Ansell, SM, Rosenblatt, JD, Savage, KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012;30(18):2183–2189.CrossRefGoogle ScholarPubMed
Chen, R, Palmer, JM, Tsai, NC, Thomas, SH, Siddiqi, T, Popplewell, L, et al. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for hodgkin lymphoma. Biol Blood Marrow Transplant 2014;20(11):1864–1868.CrossRefGoogle ScholarPubMed
Younes, A. Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma. Hematol Oncol Clin North Am 2014;28(1):27–32.CrossRefGoogle ScholarPubMed
Bartlett, NL, Chen, R, Fanale, MA, Brice, P, Gopal, A, Smith, SE, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol 2014;7:24.CrossRefGoogle ScholarPubMed
Onishi, M, Graf, SA, Holmberg, L, Behnia, S, Shustov, AR, Schiavo, K, et al. Brentuximab vedotin administered to platinum-refractory, transplant-naive Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status. Hematol Oncol 2015;33(4):187–91.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×